RDP Pharma

What RDP Pharma does

RDP Pharma AG is a privately held Swiss biotechnology company founded in 2019 and headquartered in Romanshorn, Switzerland, with research laboratories in Tulln/Vienna, Austria. The company operates with a team of approximately 30 experts focused primarily on oncology and is led by CEO Susanne Oellrich, with founders Dr. Michael Ahrweiler (CDO), Dr. Christian Kuehne (CSO, IDR pioneer), Prof. Martin Eilers (c-Myc expert), and Dr. Wolfgang Meyer. Its designated board includes Dr. Ramesh Kumar (ex-BMS, ex-Onconova) and advisor Prof. Axel Zander.

The company's core asset is the proprietary PromptDegrader™ platform, an AI-driven rational-design system for generating small-molecule degraders that target intrinsically disordered regions (IDRs) of proteins — historically considered 'undruggable' due to their lack of stable structure. The platform engages multi-ligase pathways triggering proteasomal, lysosomal, and autophagic degradation, with claims of superiority to PROTACs/glues (no hook effect, optimized PK/PD, reduced acquired-resistance potential). Its pipeline comprises a c-Myc Degrader (multiple myeloma, Burkitt's lymphoma, lung, triple-negative breast, colorectal, and other solid tumors; IND-enabling studies targeted for 2026), VS035 E7 Degrader (HPV-induced cervical, vulvar, anal intraepithelial neoplasia, and advanced HPV cancers), CP201 (oral alkyletherlipid approaching Phase 1 in healthy volunteers), and CROMOC (proprietary DDM drug-delivery module for biomolecule conveyance into tumor cells). The c-Myc program is described as targeting approximately 70% of human cancers and representing a >$110B+ targeted therapy market opportunity, supported by demonstrated dose-dependent reduction in CD138+ multiple myeloma cell viability and significant tumor growth inhibition in gold-standard xenograft models.

RDP Pharma is pre-revenue and operates an enterprise partnering business model, pursuing pharmaceutical co-development, licensing, and commercialization agreements rather than independent commercialization. Revenue mechanics are anticipated to derive from licensing royalties and milestone payments. The company markets through LinkedIn, scientific conference participation (AACR, IPVC), and direct outreach led by Dr. Michael Ahrweiler. Pricing has not been publicly disclosed.

Name

RDP Pharma

Legal name

RDP Pharma AG

Website

https://www.rdp-pharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

RDP Pharma AG is a privately held Swiss biotech developing the proprietary PromptDegrader™ platform for AI-driven targeted protein degradation of intrinsically disordered region proteins. The company targets c-Myc-driven and HPV-induced cancers through out-licensing and co-development partnerships with pharmaceutical firms.

Ownership category

akta.pro rank

Product category

Oncology Drug Development

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Targeted protein degradation
• Oncology therapeutics
• Small molecule degraders
• Intrinsically disordered proteins
• Protein modulation platform

Headquarters

HQ city

Romanshorn

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical Licensing and Co-development: Pre-revenue biotech seeking strategic partnerships for co-development and potential licensing of their drug candidates including c-Myc degrader, E7 degrader, CP201, and CROMOC.
2. Partnership and Collaboration Revenue: Seeking partners to support development of innovative products. Revenue model based on strategic partnerships, co-development agreements, and potential future product commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

RDP Pharma AG develops a proprietary PromptDegrader™ platform for Targeted Protein Degradation (TPD) of intrinsically disordered region (IDR) proteins, using AI-driven rational design of oral small-molecule degraders. Its pipeline includes the E7 Degrader (VS035) for HPV-induced cancers, a MYC Degrader for multiple myeloma and solid tumors, the CROMOC drug delivery module, and CP201 oral alkyletherlipid for cancer treatment.

Product overview

RDP Pharma AG is a privately held Swiss biotech (est. 2019) developing a proprietary PromptDegrader™ Platform for targeted protein degradation of intrinsically disordered regions (IDRs), which have historically been considered 'undruggable.' The platform enables AI-driven rational design of small-molecule degraders targeting multiple degradation pathways (proteasomal, lysosomal, and autophagic). The company pipeline includes: VS035 (E7 Degrader) for HPV-induced cancers, a MYC Degrader for multiple myeloma and solid tumors, CROMOC (drug delivery module) for liver and lung cancer, and CP201 (alkyletherlipid) for cancer treatment approaching Phase 1.

Differentiator

Problem solved

Functional benefit

Brands

• PromptDegrader™: First-in-class platform for Targeted Protein Degradation of intrinsically disordered regions of proteins to balance protein homeostasis in oncology, neurology, innate and adaptive immune response, virology and ageing.
• VS035 (E7 Degrader)
• CROMOC
• CP201

Products and services

• PromptDegrader™ Platform

Quantifiable outcome

• Significant tumor growth inhibition demonstrated in gold-standard xenograft models with well-tolerated oral doses
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• EDDC (Experimental Drug Development Centre, Singapore)coreStrategic or Co-development PartnerCo-development with Singapore's EDDC for an anti-inflammatory target to further validate the platform approach. This collaboration represents a strategic validation of RDP's PromptDegrader™ technology for additional therapeutic applications.
• University of WürzburgcoreStrategic or Co-development PartnerCollaboration with Prof. Martin Eilers (c-Myc expert, co-founder) for c-Myc/RNA interaction patent applications and ongoing scientific validation.
• University of PadovacoreStrategic or Co-development PartnerCollaboration with Prof. Stefano Moro for NCE lead series methods patents and platform technology development.
• Med University GrazsupportingTechnology or IntegrationAcademic collaboration for research and development activities.
• MIT and HarvardcoreStrategic or Co-development PartnerCollaboration with Prof. S. Vos for c-Myc/RNA interaction patent applications.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation via PROTAC chemistry, with multiple clinical-stage oncology programs (e.g., ARV-471, ARV-110). Most directly comparable because both companies commercialize small-molecule protein degraders built on proprietary platforms and pursue similar pharma partnering/Business Development monetization strategies.
• Kymera Therapeutics: Clinical-stage biotech with a proprietary targeted protein degradation platform (Pegasus) advancing immunology and oncology programs. Comparable to RDP as a platform-based degrader company targeting previously undruggable proteins via a differentiated mechanism.
• C4 Therapeutics: TPD biotech combining molecular glues and catalytic degraders, with clinical-stage oncology assets. Comparable as a protein-degradation platform company pursuing first-in-class degrader chemistries against oncology targets.
• Nurix Therapeutics: Clinical-stage TPD company (DELigase platform) addressing oncology and immunology indications via targeted small-molecule degraders. Directly comparable as a peer in protein-degradation platform licensing and partner-driven business model.
• BioTheryX: Clinical-stage TPD company developing bifunctional small-molecule degraders (PHOM) for oncology. Directly comparable to RDP because it is also an early-stage protein degradation biotech with multiple oncology-targeted programs.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders for oncology and inflammatory diseases with a focus on previously undruggable targets. Highly comparable as a degradation-platform peer with multiple programs and similar BD model.

Emerging players

• Neomorph: TPD company applying molecular glues and a DEL-based discovery platform to address previously undruggable targets. Comparable as an emerging degradation-platform peer pursuing BD-driven monetization.
• Foghorn Therapeutics: Biotech targeting chromatin dysregulation in cancer and other diseases via small-molecule modulators. Comparable due to its focus on historically undruggable oncology targets and platform-driven development approach.
• Amphista Therapeutics: TPD company developing small-molecule targeted protein degraders focused on next-generation non-PROTAC mechanisms. Comparable to RDP because both companies emphasize novel degrader chemistries distinct from classical PROTACs.

Broad incumbents

• Cullinan Oncology: Diversified oncology biotech advancing multiple clinical-stage programs across modalities including small molecules and biologics. A broader incumbent used as a relevant analogy for the partnered, multi-asset oncology strategy RDP is pursuing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rdp-pharma-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RDP Pharma